Long‐term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Long‐term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis

Published:2020-03-05 Issue:5 Volume:36 Page:
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Zhang Xiaodan¹^ORCID,Zhong Zhen²,Li Yanli¹,Li Wangen¹

Affiliation:

1. Department of EndocrinologyThe Second Affiliated Hospital of Guangzhou Medical University Guangzhou China

2. Department of EndocrinologyThe First People's Hospital of Nankang District Ganzhou China

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.3303

Reference72 articles.

1. SGLT2 inhibitors in the management of type 2 diabetes

2. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

3. Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?

4. SGLT2 Inhibitors and the Diabetic Kidney

5. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute kidney injury events in patients with diabetes using sodium glucose transporter 2 inhibitors: a meta-analysis of cohort studies;Acta Diabetologica;2024-03-05

2. Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes;Diabetes Epidemiology and Management;2023-04

3. Therapeutic Interventions of Novel SGLT2 Inhibitors Against Metabolic Disorders: Transforming the Association into Perspectives;Endocrine, Metabolic & Immune Disorders - Drug Targets;2021-12

4. Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Frontiers in Pharmacology;2021-07-19

5. Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM);Diabetes mellitus;2021-07-14